It is currently Wed Aug 23, 2017 5:27 pm



All times are UTC - 5 hours [ DST ]


Our Sponsors





Post new topic Reply to topic  [ 2 posts ] 
Author Message
 Post subject: new product
PostPosted: Thu Jun 18, 2015 3:50 pm 
Offline
Long Time Member
Long Time Member

Joined: Thu Aug 08, 2013 5:40 pm
Posts: 424
Recent article about the implant in development.
Would have to brush up on my skills or find a clinicial that would do it.
I think I have more questions now than before reading the article...
IE, taper, surgery, intolerable side effects, dosage
I hope they do a better job of detailing than the Sub folks.
Docm2

June 09, 2015
Subdermal Implant for Opioid Addiction Shows Promise

the Psychiatry Advisor take:

A small implant that would be inserted just beneath the skin and release buprenorphine, a drug used in the treatment of opioid addiction, slowly over six months, was as effective as a daily, oral version of the drug, according to results from a Phase III trial.

The device, known as Probuphine and developed by Titan Pharmaceuticals, is actually composed of ethylene-vinyl acetate (EVA) polymers that have been fashioned into tiny rods about the size of a matchstick that is designed to release buprenorphine over a long period of time. It is usually placed subdermally in the upper arm.

In the Phase III study, 177 participants were randomized to receive either the Probuphine implants or sublingual tablets for a treatment period of six months. In one group, subjects received four Probuphine implants as well as placebo sublingual tablets each day. In the second arm, participants received four placebo implants plus daily sublingual buprenorphine/naloxone tablets (8mg/day).

At six months, 96.4% of patients responded to Probuphine, compared to 87.6% of patients on oral buprenorphine, meeting the study's primary endpoint of non-inferiority. Also, 88% of those on Probuphine passed six months' worth of urine tests showing them to be opioid-free, compared to 72% of those in the oral buprenorphine group, a statistically significant difference.

The safety profile was similar between the two treatment groups.

Titan and partner Braeburn Pharmaceuticals are planning a resubmission to the FDA for Probuphine in the second half of the year. The device was rejected by the agency in 2013 and the new study was designed to address their concerns.

The companies hope Probuphine will be approved next year. If it does get an FDA nod, it would be the first marketed product to provide maintenance treatment of opioid addiction continuously for six months following a single procedure.



Probuphine is made of polymers that are fashioned into rods the size of matchsticks. Image courtesy of Titan Pharmaceuticals.


A Titan Pharmaceuticals device implanted just under the skin to release the anti-addiction medicine buprenorphine for six months prevented opioid abusers from relapsing equally as well as a daily buprenorphine, according to results from a phase III study announced Monday.

Titan and its partner Braeburn Pharmaceuticals believe positive results from the Phase III study will be sufficient to satisfy the concerns raised by the U.S. Food and Drug Administration when the device, known as Probuphine, was rejected in 2013.

A resubmission to the FDA is on track for later this year, Titan said. If approved in 2016, Probuphine, as it will be marketed, will be the first product to provide maintenance treatment of opioid addiction continuously for six months following a single procedure


Top
 Profile  
 
 Post subject: Re: new product
PostPosted: Thu Jun 25, 2015 1:08 am 
Offline
Moderator
Moderator
User avatar

Joined: Sun Jan 02, 2011 12:35 am
Posts: 2803
Location: Southwest
Thanks Docm for posting this interesting article. I wonder how many members here will go for it or maybe use it as a tapering method.

It reminds me of the Butrans Patch but in higher doses.

_________________
Don't take yourself so damn seriously


Top
 Profile  
 
Display posts from previous:  Sort by  
Post new topic Reply to topic  [ 2 posts ] 

All times are UTC - 5 hours [ DST ]


Who is online

Users browsing this forum: No registered users and 0 guests


You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot post attachments in this forum

Search for:
Jump to:  
Our Sponsors
Suboxone Forum latest topics RSS feed Subscribe to the entire forum
 

 

 
Fond Du Lac Psychiatry
Dr. Jeffrey Junig, M.D., Ph.D.

  • Board Certified Psychiatrist
  • Asst Clinical Professor, Medical College of Wisconsin

Powered by phpBB® Forum Software © phpBB Group